HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toren, A. Articles by Nagler, A. Search for Related Content PubMed PubMed Citation Articles by Toren, A. Articles by Nagler, A.

Minimal Residual Disease Post-Bone Marrow Transplantation for Hemato-Oncological Diseases

^a Pediatric Hemato/Oncology Department, The Chaim Sheba Medical Center, affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Hashomer, Israel;
^b Department of Bone Marrow Transplantation, Hadassah University Hospital and the Hebrew University, Jerusalem, Israel

Key Words. Minimal residual disease (MRD) • Restriction fragment length polymorphism (RFLP) • Variable number of tandem repeats (VNTR) • Microsatellites • Fluorescence in situ hybridization (FISH) • Southern blot • Amelogenin • Quantitative-polymerase chain reaction (PCR) • Adoptive cell-therapy • Chimerism • Thalassemia

Dr. Arnon Nagler, Dept. of Bone Marrow Transplantation, Hadassah University Hospital, 91120 Jerusalem, Israel.

The detection of minimal residual disease (MRD), which is important in cancer treatment, gained special significance in bone marrow transplantation (BMT) due to the possibility not just to detect but recently also to prevent, treat and reinduce remission in patients that relapsed post-BMT by immunotherapy. The various modern techniques of MRD detection are described including cytogenetics, analysis of restriction fragment length polymorphism, variable number of tandem repeats by Southern Blot or polymerase chain reaction (PCR), microsatellite sequences, PCR amplification products of the Y chromosome or the Amelogenin gene, quantitative PCR and fluorescence in situ hybridization. The role of MRD detection in refinement of indications for BMT, autografting, prediction of relapse, adoptive immunotherapy, mixed chimerism in nonmalignant diseases and in solid organ transplantation is discussed.

This article has been cited by other articles:

				K. M. Murphy, J. S. Cohen, A. Goodrich, P. P. Long, and C. A. Griffin Constitutional Duplication of a Region of Chromosome Yp Encoding AMELY, PRKY, and TBL1Y: Implications for Sex Chromosome Analysis and Bone Marrow Engraftment Analysis J. Mol. Diagn., July 1, 2007; 9(3): 408 - 413. [Abstract] [Full Text] [PDF]